價(jià)格 | ¥554 | ¥913 | ¥1710 |
包裝 | 2mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱(chēng):化合物 SRI-41315 | 英文名稱(chēng):SRI-41315 |
CAS:1613509-49-1 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Shipping with blue ice. |
產(chǎn)品類(lèi)別: 抑制劑 | |
貨號(hào): T61306 |
名稱(chēng) | SRI-41315 |
描述 | SRI-41315, a chemical compound, effectively addresses premature termination codons (PTCs) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells. It induces a prolonged pause at stop codons, resulting in the restoration of cystic fibrosis transmembrane conductance regulator (CFTR) expression and function. This compound achieves PTC suppression by reducing the abundance of the termination factor eRF1. Additionally, SRI-41315 synergistically enhances CFTR activity by potentiating aminoglycoside-mediated readthrough [1]. |
體外活性 | SRI-41315 exhibits target cell cytotoxicity (CC50) values >50 μM in both FRT and 16BE14o- cells [1]. SRI-41315 shows improved potency and efficacy in FRT cells that translated to 16HBE14o- cells [1]. SRI-41315 (5 μM, 20 h) depletes eRF1 levels through a proteasome-mediated degradation pathway [1]. Western Blot Analysis [1] Cell Line: CFTR-G542X 16HBEge G542X cells Concentration: 5 μM Incubation Time: 20 h Result: Depleted eRF1 levels through a proteasome-mediated degradation pathway. SRI-41315-mediated eRF1 degradation was prevented by the addition of (S)-MG132 but not the neddylation inhibitor MLN4924. |
存儲(chǔ)條件 | Shipping with blue ice. |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱(chēng) | 價(jià)格 | 公司名稱(chēng) | 報(bào)價(jià)日期 | |
---|---|---|---|---|
¥1280 |
VIP1年
|
湖北艾普蒂生物工程有限公司
|
2025-01-23 | |
¥1950 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2025-01-17 | |
¥1600.00 |
VIP9年
|
北京索萊寶科技有限公司
|
2025-01-24 |